CN101309680A - 2-苯基-1,2-乙二醇-(di)氨基甲酸酯治疗癫痫发生和癫痫的用途 - Google Patents

2-苯基-1,2-乙二醇-(di)氨基甲酸酯治疗癫痫发生和癫痫的用途 Download PDF

Info

Publication number
CN101309680A
CN101309680A CNA2006800333910A CN200680033391A CN101309680A CN 101309680 A CN101309680 A CN 101309680A CN A2006800333910 A CNA2006800333910 A CN A2006800333910A CN 200680033391 A CN200680033391 A CN 200680033391A CN 101309680 A CN101309680 A CN 101309680A
Authority
CN
China
Prior art keywords
epilepsy
formula
patient
treatment
enantiomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800333910A
Other languages
English (en)
Chinese (zh)
Inventor
R·E·特怀曼
B·赵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101309680(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN101309680A publication Critical patent/CN101309680A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CNA2006800333910A 2005-07-12 2006-07-07 2-苯基-1,2-乙二醇-(di)氨基甲酸酯治疗癫痫发生和癫痫的用途 Pending CN101309680A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69862505P 2005-07-12 2005-07-12
US60/698,625 2005-07-12

Publications (1)

Publication Number Publication Date
CN101309680A true CN101309680A (zh) 2008-11-19

Family

ID=37637731

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800333910A Pending CN101309680A (zh) 2005-07-12 2006-07-07 2-苯基-1,2-乙二醇-(di)氨基甲酸酯治疗癫痫发生和癫痫的用途

Country Status (16)

Country Link
US (1) US20070021501A1 (https=)
EP (1) EP1906946A2 (https=)
JP (1) JP2009501223A (https=)
KR (1) KR20080028485A (https=)
CN (1) CN101309680A (https=)
AR (1) AR054550A1 (https=)
AU (1) AU2006269462A1 (https=)
BR (1) BRPI0613010A2 (https=)
CA (1) CA2615127A1 (https=)
EA (1) EA200800295A1 (https=)
EC (1) ECSP088172A (https=)
IL (1) IL188728A0 (https=)
NO (1) NO20080739L (https=)
TW (1) TW200744575A (https=)
WO (1) WO2007008551A2 (https=)
ZA (1) ZA200801402B (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071424A (zh) * 2016-02-29 2018-12-21 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
CN109939092A (zh) * 2013-03-12 2019-06-28 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN112703008A (zh) * 2017-07-18 2021-04-23 创新生物肽有限公司 治疗癫痫、发作和cns疾病的经口抗炎肽
CN115192575A (zh) * 2015-08-24 2022-10-18 周格尼克斯国际有限公司 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用
US12257283B2 (en) 2019-12-19 2025-03-25 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
USRE50563E1 (en) 2017-10-31 2025-09-02 Creative Bio-Peptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
AU3304997A (en) * 1996-05-31 1998-01-05 Southern Illinois University Methods of modulating aspects of brain neural plasticity by vagus nerve stimulation
CA2360258A1 (en) * 1999-02-09 2000-08-17 Timothy L. Macdonald Felbamate derived compounds
MXPA03007717A (es) * 2001-02-27 2005-11-08 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o tratamiento de trastornos bipolares.
PL364640A1 (en) * 2001-02-27 2004-12-13 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109939092A (zh) * 2013-03-12 2019-06-28 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN109939092B (zh) * 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
CN115192575A (zh) * 2015-08-24 2022-10-18 周格尼克斯国际有限公司 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
CN109071424A (zh) * 2016-02-29 2018-12-21 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
CN109071424B (zh) * 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
CN112703008A (zh) * 2017-07-18 2021-04-23 创新生物肽有限公司 治疗癫痫、发作和cns疾病的经口抗炎肽
USRE50563E1 (en) 2017-10-31 2025-09-02 Creative Bio-Peptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
CN109920550A (zh) * 2018-12-25 2019-06-21 天津大学 一种基于dMRI研究青少年肌阵挛性癫痫的方法
US12257283B2 (en) 2019-12-19 2025-03-25 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
CN115501344A (zh) * 2022-09-29 2022-12-23 重庆医科大学 一种铁螯合剂的应用

Also Published As

Publication number Publication date
CA2615127A1 (en) 2007-01-18
WO2007008551A3 (en) 2008-06-19
KR20080028485A (ko) 2008-03-31
BRPI0613010A2 (pt) 2010-12-14
NO20080739L (no) 2008-04-10
TW200744575A (en) 2007-12-16
ZA200801402B (en) 2009-10-28
EP1906946A2 (en) 2008-04-09
IL188728A0 (en) 2008-11-03
EA200800295A1 (ru) 2008-12-30
US20070021501A1 (en) 2007-01-25
JP2009501223A (ja) 2009-01-15
AR054550A1 (es) 2007-06-27
ECSP088172A (es) 2008-03-26
WO2007008551A2 (en) 2007-01-18
AU2006269462A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
Mechoulam et al. Cannabidiol: an overview of some pharmacological aspects
KR101783632B1 (ko) 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
CN101287459A (zh) 用于治疗神经变性性疾病的氨基甲酸酯化合物
KR102615486B1 (ko) 펜플루라민을 사용하여 레녹스-가스토 증후군을 치료하는 방법
EP2345455B1 (en) Lacosamide for the treatment of hyperexcitability disorders associated with sodium channel dysfunction
US11690832B2 (en) Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
Müller Management of endocrine disease: childhood-onset craniopharyngioma: state of the art of care in 2018
CN101309680A (zh) 2-苯基-1,2-乙二醇-(di)氨基甲酸酯治疗癫痫发生和癫痫的用途
KR101828934B1 (ko) 양극성 장애의 치료방법
CN101056629B (zh) 2-苯基-1,2-乙二醇-(二)氨基甲酸酯在制备治疗癫痫发生的药物中的用途
Gnirs Ciclosporin treatment of suspected granulomatous meningoencephalomyelitis in three dogs
Schocket et al. Bilateral optic nerve infiltration in central nervous system leukemia
MX2007004491A (es) Compuestos de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos.
Sonras et al. Surgical outcome in hippocampal sclerosis following selective amygdalo-hippocampectomy
Sharma et al. Tailoring MAPK Pathways: New Therapeutics Avenues for Managing Alzheimer’s Diseases
Yurtluk et al. Glioblastoma development following stereotactic radiosurgery for an arteriovenous malformation: A case report
HK40082682A (en) Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
Campana et al. Exogenous erythropoietin protects against DRG apoptosis and pain following nerve crush injury
Niebauer Glutamate-receptor antagonist drugs as possible neuroprotectants in a model of status epilepticus
CN121419776A (zh) 治疗多发性硬化症的伊博格碱
Gilbert et al. Conventional anticonvulsant drugs in the guinea-pig kindling model of partial seizures: effects of repeated administration
Gavrilova et al. Clinical efficacy of exelon in patients with Alzheimer's disease
Tajerian The SPARC-null mouse model of low back pain: Mechanism, Treatment, and Translation to Humans
Congress Canadian Neurological Sciences Federation
HK1224600A (en) Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20081119